Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 19;11(11):1819.
doi: 10.3390/cancers11111819.

Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma

Yutaka Tsukune  1 , Makoto Sasaki  1 , Norio Komatsu  1
Affiliations
Review

Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma

Yutaka Tsukune et al. Cancers (Basel). .

Abstract

Reactivation of hepatitis B virus (HBV) is a well-known complication in patients with hematological malignancies during or after cytotoxic chemotherapy. If the initiation of antiviral therapy is delayed in patients with HBV reactivation, these patients can develop severe hepatitis and may die of fulminant hepatitis. The preventive strategy for HBV reactivation in patients with malignant lymphoma has already been established based on some prospective studies. As there was an increased number of novel agents being approved for the treatment of multiple myeloma (MM), the number of reported cases of HBV reactivation among MM patients has gradually increased. We conducted a Japanese nationwide retrospective study and revealed that HBV reactivation in MM patients is not rare and that autologous stem cell transplantation is a significant risk factor. In this study, around 20% of all patients with HBV reactivation developed HBV reactivation after 2 years from the initiation of therapy, unlike malignant lymphoma. This might be due to the fact that almost all of the patients received chemotherapy for a long duration. Therefore, a new strategy for the prevention of HBV reactivation in MM patients is required.

Keywords: autologous stem cell transplantation; hepatitis B virus; multiple myeloma; novel agents; reactivation.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests related to this publication.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ocama P., Opio C.K., Lee W.M. Hepatitis B virus infection: Current status. Am. J. Med. 2005;118:1413. doi: 10.1016/j.amjmed.2005.06.021. - DOI - PubMed
    1. World Health Organization Hepatitis: Fact Sheet. [(accessed on 9 September 2019)];2019 Jul; Available online: https://www.who.int/en/news-room/fact sheets/detail/hepatitis-b.
    1. Kusumoto S., Tanaka Y., Ueda R., Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J. Gastroenterol. 2011;46:9–16. doi: 10.1007/s00535-010-0331-4. - DOI - PubMed
    1. Yeo W., Chan P.K., Ho W.M., Zee B., Lam K.C., Lei K.I., Chan A.T., Mok T.S., Lee J.J., Leung T.W., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 2004;22:927–934. doi: 10.1200/JCO.2004.05.161. - DOI - PubMed
    1. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., Cheung M., Zhang H.Y., Lie A., Ngan R., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–1749. doi: 10.1053/j.gastro.2003.09.026. - DOI - PubMed
  NODES
twitter 2